USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis

Biochem Biophys Res Commun. 2009 Oct 16;388(2):366-71. doi: 10.1016/j.bbrc.2009.08.015. Epub 2009 Aug 8.

Abstract

Paclitaxel (also known as Taxol) is a well-known anticancer agent that blocks cell mitosis and kills tumor cells, and is often used in clinic to treat cancers. Despite the success of Paclitaxel, the development of drug resistance prevents its clinical applicability. Here, we screened an siRNA library against the entire human genomes using HeLa cells, and have find that lack of USP15 (ubiquitin-specific protease 15) causes Paclitaxel resistance. We also observed the decreased expression of USP15 in Paclitaxel-resistant human ovarian cancer samples. In addition, we have demonstrated that USP15 plays an essential role for stability and activity of caspase-3 during Paclitaxel-induced apoptosis. Thus, USP15 may be a candidate diagnostic marker and therapeutic target for Paclitaxel-resistant cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis*
  • Caspase 3 / biosynthesis*
  • Drug Resistance, Neoplasm / genetics
  • Endopeptidases / genetics
  • Endopeptidases / metabolism*
  • Enzyme Activation
  • Gene Knockdown Techniques
  • HeLa Cells
  • Humans
  • Paclitaxel / pharmacology*
  • RNA, Small Interfering / genetics
  • Tubulin Modulators / pharmacology*
  • Ubiquitin-Specific Proteases

Substances

  • Antineoplastic Agents, Phytogenic
  • RNA, Small Interfering
  • Tubulin Modulators
  • Endopeptidases
  • USP15 protein, human
  • Ubiquitin-Specific Proteases
  • Caspase 3
  • Paclitaxel